About Kaleido
Kaleido is a company based in Utrecht (Netherlands) founded in 2013 by Tim Oakes. It operates as a HealthTech and Direct-to-Consumer (D2C). Kaleido has raised $183.29 million across 5 funding rounds from investors including EQT, Kreos Capital and Life Sciences Partners. Kaleido offers products and services including Kaleido Insulin Pump and DBLG1 Hybrid Closed Loop System. Kaleido operates in a competitive market with competitors including Tandem Diabetes, Modular Medical, LenoMed, Asante Solutions and Sooil Development, among others.
- Headquarter Utrecht, Netherlands
- Founders Tim Oakes
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Vicentra B.V.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$183.29 M (USD)
in 5 rounds
-
Latest Funding Round
$13 M (USD), Series D
Jan 08, 2026
-
Investors
EQT
& 12 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Kaleido
Kaleido offers a comprehensive portfolio of products and services, including Kaleido Insulin Pump and DBLG1 Hybrid Closed Loop System.
Insulin pump designed for flexible diabetes management daily.
System integrated for automated insulin delivery control.
People of Kaleido
Unlock access to complete
Funding Insights of Kaleido
Kaleido has successfully raised a total of $183.29M across 5 strategic funding rounds. The most recent funding activity was a Series D round of $13 million completed in January 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Kaleido
Kaleido has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include EQT, Kreos Capital and Life Sciences Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Partners in Equity is focused on impact investments for environmental solutions.
|
Locked | Locked | Locked | |
|
Private equity investments in life sciences businesses are managed.
|
Locked | Locked | Locked | |
|
AI, deeptech, and healthcare tech companies are funded by Inkef.
|
Locked | Locked | Locked |
Investor details for Kaleido
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Kaleido
Investment portfolio details for Kaleido
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Kaleido
Detailed financials for Kaleido
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Kaleido Comparisons
Peer comparison for Kaleido
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Kaleido
Kaleido operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Tandem Diabetes, Modular Medical, LenoMed, Asante Solutions and Sooil Development, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of devices for continuous glucose monitoring and manual insulin delivery
|
|
| Locked | Locked | Locked |
Insulin pumps are developed for continuous delivery to diabetic patients.
|
|
| Locked | Locked | Locked |
Developer of closed loop insulin delivery devices
|
|
| Locked | Locked | Locked |
Insulin pump systems are developed and customized by Asante Solutions.
|
|
| Locked | Locked | Locked |
Develops insulin pumps and apps for diabetes care and blood sugar monitoring.
|
Detailed competitors of Kaleido
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Kaleido
Complete news archive for Kaleido
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kaleido
Kaleido was founded in 2013 and raised its 1st funding round 3 years after it was founded.
Kaleido is headquartered in Utrecht, Netherlands.
Thomas Arnold is the current CEO of Kaleido.
Kaleido is a funded company, having raised a total of $183.29M across 5 funding rounds to date.
Kaleido, operated by ViCentra B.V., is dedicated to providing advanced diabetes management solutions through its innovative insulin pump technology. The company offers the Kaleido Insulin Pump, designed for flexibility with customizable wear options and integrated with the DBLG1 Hybrid Closed Loop system for automated insulin delivery. Serving the healthcare sector, particularly in diabetes care, Kaleido emphasizes user freedom and personalized care with features like self-learning algorithms and 247 data insights. Its solutions are currently available in the Netherlands and Germany, targeting adults with type 1 diabetes.
Kaleido's top competitors include Tandem Diabetes, Modular Medical and LenoMed.
Kaleido offers Kaleido Insulin Pump and DBLG1 Hybrid Closed Loop System.
Kaleido has 13 investors. Key investors include EQT, Kreos Capital, Life Sciences Partners, Partners in Equity, and Direct Recruiters.